Next Article in Journal
Effects of Freeze–Thaw Cycles on Uptake Preferences of Plants for Nutrient: A Review
Previous Article in Journal
Photomorphogenic and Biochemical Effects of Radiation and Nitrate Availability on the Red Alga Plocamium cartilagineum
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Plants
Volume 14
Issue 7
10.3390/plants14071118
plants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chemical Profile Analysis of Prosopis laevigata Extracts and Their Topical Anti-Inflammatory and Antibacterial Activities

by
Manasés González-Cortazar
1,*,
David Osvaldo Salinas-Sánchez
2,3,*,
Maribel Herrera-Ruiz
1,
Paulina Hernández-Hernández
1,3,
Alejandro Zamilpa
1,
Enrique Jiménez-Ferrer
1,
Beatriz E. Utrera-Hernández
4,
Ma. Dolores Pérez-García
1,
Ana S. Gutiérrez-Roman
1,5 and
Ever A. Ble-González
4
1
Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1, Col. Centro, Xochitepec 62790, Morelos, Mexico
2
Centro de Investigación en Biodiversidad y Conservación (CIByC), Universidad Autónoma del Estado de Morelos (UAEM), Av. Universidad 1001, Col. Chamilpa, Cuernavaca 62209, Morelos, Mexico
3
Escuela de Estudios Superiores del Jicarero (EESJ), Universidad Autónoma del Estado de Morelos, Carretera Galeana-Tequesquitengo s/n Col. el Jicarero, Jojutla 62909, Morelos, Mexico
4
División Académica de Ciencias Básicas, Universidad Juárez Autónoma de Tabasco, Carretera Cunduacán-Jalpa Km. 0.5, Cunduacán 86690, Tabasco, Mexico
5
Centro de Desarrollo de Productos Bióticos, Instituto Politécnico Nacional, Carretera Yautepec-Jojutla s/n km 85, San Isidro 62739, Morelos, Mexico
*
Authors to whom correspondence should be addressed.
Plants 2025, 14(7), 1118; https://doi.org/10.3390/plants14071118
Submission received: 13 February 2025 / Revised: 14 March 2025 / Accepted: 1 April 2025 / Published: 3 April 2025
(This article belongs to the Section Phytochemistry)
Browse Figures
Review Reports Versions Notes

Abstract

There are two major global morbidity and mortality problems in the health sector: inflammation, which is the physiological process that, in acute and chronic conditions, gradually causes the loss of the body’s functionality, leading to severe damage to health; and microbial diseases, which are caused by pathogenic microorganisms such as bacteria. In the present study, the anti-inflammatory effects of three extracts of mesquite (Prosopis laevigata)—n-hexane (PH), dichloromethane (PD), and methanol (PM)—were assessed in a mouse model of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear oedema, and the antimicrobial effects against 14 microorganisms were assessed using the broth microdilution method. The extracts inhibited ear oedema by 60.81% (PH), 75.96% (PD), and 60.29% (PM). The most active anti-inflammatory extract (PD) was fractionated through chromatography, and three fractions (PDR3, PDR6, and PDR7) were evaluated. One of the most active fractions (PDR7) was purified via column chromatography, and ethyl veratrate (VE, 1) was isolated and identified. VE inhibited ear oedema by 85.1%. The anti-inflammatory effect is evidenced by the quantification of two pro-inflammatory cytokines (IL-10 and TNF-α). The PD extract, the PDR7 fraction, and the compound present an IL-10 concentration of 11.8, 18.9, and 36.5 pg/mg of protein, values significantly higher than the group that received only phorbol ester (* p < 0.05). These treatments also significantly decreased the concentration of TNF-α (* p < 0.05) to 197.6, 241.9, and 247.0 pg/mg protein, respectively. The PM extract showed the most pronounced antimicrobial effect, with a minimum inhibitory concentration (MIC) of <12.5 µg/mL for almost all the 14 tested strains, followed by the PD and PH extracts. Chromatographic fractionation of the PM extract yielded the PMR6, PMR7, and PMR10 fractions that inhibited all tested microorganisms with a MIC between 6.25 and 200 µg/mL. Compound 1 was active on five strains, with a concentration between 2 and 8 µg/mL. High-performance liquid chromatography analysis and comparison with commercial standards allowed for the identification of rutin (2) and quercetin 3-O-glucoside (3). Gas chromatography–mass spectrometry analysis of the PH and PD extracts allowed for the identification of fatty acids, terpenes, and phenols.

Graphical Abstract

1. Introduction

Antimicrobial resistance is a very serious global public health problem and represents an urgent threat due to the presence of resistance to antimicrobial agents [1]. These resistant microorganisms—including bacteria, fungi, and parasites, among others—cause infections and generate great morbidity and mortality throughout the world [2]. According to recent reports, it is estimated that by 2050, there will be 10,000 deaths each year due to this public health problem [3]. Antimicrobial agents have several mechanisms of action, including the inhibition of cell wall synthesis, protein synthesis, nucleic acid synthesis, and metabolic pathways, as well as the depolarisation of the cell membrane [4]. Resistance can result from numerous phenomena, including the modification of targets, where the microorganism acquires a mutation that alters the drug binding site; the production of inactivating enzymes (e.g., beta-lactamase, which breaks down the beta-lactam ring of penicillin); efflux pumps in the membranes that expel drugs (e.g., tetracycline); membrane impermeability (e.g., the outer membrane in Gram-negative bacteria); and alternative metabolic pathways that utilise enzymes that are not inhibited by the available antimicrobial agents [4,5,6]. After a microorganism causes an infection, inflammation is one of the responses to the pathogen [7,8]. Inflammation is a natural defense response of the body’s cells and tissues against endogenous or exogenous agents (e.g., bacterial and fungal infections, trauma, necrosis, chronic degenerative diseases, and chemical agents).
Traditional medicine using medicinal plants plays a crucial role in the treatment of diseases, including microbial infections and excessive inflammation. Indeed, extracts from these plants may help to enhance or complement medical treatments for inflammatory diseases while preventing antimicrobial resistance [9,10]. Many plant species synthesise natural products with direct antimicrobial activity, among which flavonoids, terpenes, and alkaloids stand out. For example, garlic (Allium sativum) has shown efficacy against multidrug-resistant bacteria [11]. Green tea (Camellia sinensis), which has a high phenolic compound content, can interfere with bacterial efflux pumps, which are responsible for expelling antibiotics from the cell [12]. Likewise, secondary metabolites isolated from plants, such as rosmarinic acid, enhance the effects of antibiotics against resistant bacteria [13]. In addition, some plants are used to suppress inflammation, whether chronic or acute. The mechanism of action is quite variable. For example, gingerol in ginger (Zingiber officinale) inhibits the release of proinflammatory cytokines such as interleukin 1 (IL-1), IL-6, and tumour necrosis factor alpha (TNF-α) and activates nuclear factor kappa B (NF-κB), which regulates the inflammatory response [14].
The Prosopis genus comprises more than 44 species distributed mainly in Africa, America, and Asia. These species are generally small trees or shrubs. Herbal preparations obtained from Prosopis species have various ethnomedicinal uses, including to treat asthma, rheumatism, poisonous bites, pests, and plant diseases. The compounds that have been isolated and identified include phenolics, alkaloids, flavonoids, and terpenes [15]. Their pharmacological properties include antibacterial, antifungal, anti-inflammatory, antitumor, and analgesic activities [16,17].
Prosopis laevigata, commonly called smooth mesquite, is a small tree or shrub widely distributed throughout Mexico. In traditional Mexican medicine, it is used to treat eye diseases, rash, and digestive system disorders [18]. P. laevigata leaves have also been reported to have antimicrobial activity [19,20], anthelmintic activity [21], and antioxidant and cardioprotection potential [19]. Two alkaloids have been isolated and identified: prosopine and prosopinine [22,23]. In a recent study, researchers identified a flavonoid known as isorhamnetin from the ethyl acetate fraction; it prevented nematicidal activity against the eggs and larvae of Haemonchus contortus [21]. This work aimed to determine the chemical composition of three P. laevigata extracts—n-hexane (PH), dichloromethane (PD), and methanol (PM)—as well as their anti-inflammatory properties in a mouse model of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear oedema and as an antibacterial against 14 microorganisms.

2. Results

2.1. High-Performance Liquid Chromatography (HPLC) Analysis of the PM Extract

The HPLC chromatograms (Figure 1) show the chemical profile of the PM extract, as well as the rutin (2) and quercetin 3-O-glucoside (3) standards. A chromatographic comparison of the retention times and ultraviolet (UV, see in Supplementary Materials) spectra with the standards indicated that the peaks at 8.81 min (λmax = 212.2, 256.9.7, and 355.3 nm) correspond to compound 2 and 9.11 min (λmax = 212.2, 255.7, and 355.3 nm) to compound 3 (see Figure 2).

2.2. The Gas Chromatography–Mass Spectrometry (GS-MS) Profiles of the PH and PD Extracts

The phytoconstituents present in the PH extract are shown in Table 1. The chemicals include alkanes (1,5,4-dibromotetrapentacontane, tetracontane, heptacosane, and tetratetracontane), a fatty acid (hexanedioic acid), an alkylated phenol (6,6′-di-tert-butyl-4,4′-diethyl-2,2′-methylenediphenol), and a terpene (squalene).
Table 2 presents the chemical constituents of the PD extract. They include a benzofuran (6-hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydrobenzofuran-2(4H)-one), a diterpene alcohol (phytol), and a fatty acid (bis[(2S)-2-ethylhexyl] hexanedioate).

2.3. Anti-Inflammatory Effect of the P. laevigata Extracts

Table 3 shows the anti-inflammatory activity of the PH, PD, and PM extracts based on the mouse TPA-induced ear oedema model (applying 1 mg/ear). The PD extract had the greatest anti-inflammatory effect; it inhibited oedema by 75.96% (2.74 mg), higher than the positive control (indomethacin: 65.08% and 4 mg). The PH and PM extracts showed 60.81% (4.00 mg) and 60.29% (4.54 mg) inhibition, respectively.

Structural Elucidation of Compound (1)

Compound (1) was isolated as a yellow powder. In the UV spectrum, the compound showed a λmax of 211, 249.8, 307.7, and 347 nm, characteristic of a phenolic compound. The 13C nuclear magnetic resonance (NMR) spectrum of 1 (Table 4, see figure in Supplementary Material) showed 11 peaks, of which 4 are quaternary, 3 are methines, 1 is a methylene, and 3 are methyls. The 1H NMR spectrum showed an ABX aromatic ring system at δ 7.58 (1H, d, J = 2.0 Hz, H-3), 6.77 (1H, d, J = 8.9 Hz H-6), and 7.57 (1H, dd, J = 2.0 and 8.4 Hz, H-7). Additionally, there were signals at δ 3.83 (s) and 3.82 (s), which, according to HSQC, correspond to two methoxyls at δ 55.8; and the presence of an ethyl acetate at δ 4.25 (2H, q, 7.5) and 1.29 (3H, t, 6.8), which are assigned to H-1′ and H-2′, respectively. According to the analysis of the spectroscopic data (Table 3), it is proposed that 1 is a tri-substituted aromatic ring derived from veratric acid, specifically ethyl veratrate (VE, 1) (see Figure 2).
Table 4. The proton (1H) and carbon (13C-NMR) nuclear resonance spectroscopy data for compound 1 (CDCl3, 600 MHz).
Table 4. The proton (1H) and carbon (13C-NMR) nuclear resonance spectroscopy data for compound 1 (CDCl3, 600 MHz).
Position δ1H (δ in ppm, J in Hz)
1		 δ13C (HSQC)
1		 HMBC (J2–3)
1 166.27.57, 7.45, 6.77, 4.26
2 122.9
37.45 (1H, d, 2.0)110.1123.3, 148.5, 152.8, 166.5
4 148.5
5 152.8
66.77 (1H, d, 8.9)111.8122.9, 148.5, 152.8
77.57 (1H, dd, 2.0, 8.9)123.3111.8, 148.5, 152.8, 166.2
1′4.25 (2H, q, 7.5)60.614.2, 166.2
2′1.29 (3H, t, 6.8)14.260.6
OCH33.83, s55.8152.8
OCH33.82, s55.8148.5
Plants 14 01118 g002
Figure 2. Chemical structures identified in Prosopis laevigata: ethyl veratrate (1); quercetin 3-O-rutinoside o rutin (2); quercetin 3-O-glucoside (3).
Figure 2. Chemical structures identified in Prosopis laevigata: ethyl veratrate (1); quercetin 3-O-rutinoside o rutin (2); quercetin 3-O-glucoside (3).
Plants 14 01118 g002

2.4. Anti-Inflammatory Effect of PD Extract Fractions and Compound (1)

The PD extract was separated into eight fractions to identify the active principles responsible for the anti-inflammatory activity. The PDR3, PDR6, and PDR7 fractions were tested in the mouse TPA-induced ear oedema model. They decreased oedema by 5.55 ± 2.03 mg, 4.41 ± 2.55 mg, and 6.23 ± 1.7 mg, respectively, representing a reduction of 56.58%, 65.45%, and 51.23%, respectively. They were not significantly different from the effect of treatment with indomethacin (Table 5).

Quantification of Pro-Inflammatory the Cytokines IL-10 and TNF-α

In Figure 3A, it is shown that the group of mice that did not receive TPA (Basal) have an IL-10 concentration of 37.5 pg/mg of protein, a value that is significantly higher than the group that received only phorbol ester (* p < 0.05). Indomethacin (INDO), as well as treatments derived from P. laevigata, significantly increase the values of this pro-inflammatory cytokine when compared with the group without treatment (TPA, * p < 0.05), with the treatment with compound 1 being the one that shows the greatest effect on this variable.
Quantification of the pro-inflammatory cytokine TNF-α is shown in Figure 3B. It can be observed that the values of the Basal group, as well as those who received Indo at 1 mg/ear, were statistically lower than the group that received TPA. Treatments with PD, PDR7, and compound 1 were able to significantly decrease not only the oedema but also the concentrations of this pro-inflammatory molecule (* p < 0.05).

2.5. Antibacterial Activity

Antibacterial activity was determined based on the minimum inhibitory concentration (MIC) of the PH, PD, and PM extracts against 14 bacterial or fungal strains (Table 6). The PM extract presented an antibacterial effect against the 14 evaluated strains. For S. aureus ATCC 29213, methicillin-resistant S. aureus ATCC 43300, S. epidermidis ATCC 35984, S. epidermidis ATCC 12228, S. epidermidis ATCC 49134, S. haemolyticus derived from ATCC 29970, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. dublin ATCC 9676, E. cloacae ATCC 700323, and C. albicans ATCC 10231, the MIC was <12.5 µg/mL. For E. faecalis ATCC 29212 and E. coli ATCC 8739, the MIC values were 50 and 200 µg/mL, respectively. It is worth noting that the PD and PM extracts had MICs of 12.5 and 6.25 µg/mL, respectively, against the methicillin-resistant strain (i.e., methicillin-resistant S. aureus ATCC 43300).

2.6. Antibacterial Activity of Fractions and Compound 1

The PMR2, PMR5, PMR6, PMR7, and PMR10 fractions of the PM extract presented antimicrobial activity (Table 7). The PMR6, PMR7, and PMR10 fractions presented an MIC of ≤25 g/mL for 12 of the microorganisms, namely, S. aureus ATCC 29213, methicillin-resistant S. aureus ATCC 43300, S. epidermidis ATCC 35984, S. epidermidis ATCC 12228, S. epidermidis ATCC 49134, S. haemolyticus derived from ATCC 29970, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. dublin ATCC 9676, E. cloacae ATCC 700323, and C. albicans ATCC 10231, and an MIC ≥ 25 µg/mL for E. coli ATCC 8739.
The PDR7 fraction of the PD extract presented an MIC of ≥25 µg/mL for seven strains, namely, methicillin-resistant S. aureus ATCC 43300, S. epidermidis ATCC 35984, E. faecalis ATCC 29212, P. aeruginosa ATCC 27853, E. coli ATCC 8739, S. dublin ATCC 9676, and E. cloacae ATCC 700323, and compound 1 had an MIC ≤ 8 µg/mL for five strains, namely, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. dublin ATCC 9676, and C. albicans ATCC 10231. It is important to mention that the PMR6, PMR7, and PMR10 fractions inhibited the methicillin-resistant strain (methicillin-resistant S. aureus ATCC 43300) at concentrations of 6.25 and 25 μg/mL. Gentamicin was used as a positive control at a concentration of 10 µg/mL as it is a first-line drug in the treatment of microbial infections.

3. Discussion

P. laevigata has been used in Mexico to treat eye diseases, rash, and digestive system disorders. It is also used to treat dysentery, an infectious disease characterised by intestinal inflammation and bloody diarrhoea caused by the Shigella bacterium or an amoeba and spread through contaminated food or dirty water [24,25,26]. Based on these data, we selected the aerial parts of this plant and evaluated the biological activity of the PH, PD, and PM extracts.
TPA is a skin irritant, the action of which causes keratinocytes and epidermal dendritic cells to produce inflammatory molecules such as TNF-α, causing acute inflammation with the recruitment of immune cells, namely, neutrophils, macrophages, and mast cells, from the skin tissue [27,28]. The particular mechanism on which TPA exerts its effect is that it induces intracellular signaling pathways through the activation of protein kinase C (PKC), including PI3K/AKT/NF-κB signaling, STAT3 signaling, and the consequent generation of inflammatory mediators such as TNF-α, IL-1β, IL-6, iNOS, COX-2, keratinocyte-derived chemokine, and macrophage inflammatory protein (MIP-2), among other chemokines and prostaglandins which maintain inflammation [29].
The anti-inflammatory activity of Prosopis juliflora and Prosopis alba extracts has been studied. Researchers have attributed this activity to alkaloids and phenolic compounds present in the aerial parts of these species [30,31]. In the present study, the administration of the PD extract (1 mg/ear) showed the highest percentage of inhibition (75.96%). This activity could be related to the phytol content (70.11%) in the PD extract. Phytol is a diterpene belonging to the group of unsaturated branched-chain alcohols. It has been shown to have several pharmacological properties, such as antinociceptive, anti-inflammatory, and antioxidant properties. This compound reduces plantar inflammation induced by different inflammatory agents. Its anti-inflammatory effect is due to its ability to decrease myeloperoxidase (MPO) activity, the levels of the pro-inflammatory cytokines TNF-α and IL-1β; the concentration of malondialdehyde (MDA) [32], and the release of serotonin, bradykinin, prostaglandin, and histamine [33]. On the other hand, Carvalho et al. [34] showed that phytol inhibits the release of the inflammatory mediators TNF-α, IL-6, and cyclooxygenase 2 (COX2) in complete Freund’s adjuvant–induced rheumatoid arthritis by inhibiting the activation of the p65 pathway of NF-κB through dephosphorylation/inhibition of p38 [34]. It is observed in the present work that PD, PDR7, and compound 1 were able to decrease the levels of TNF-α and increase those of IL-10 in the homogenate of mouse ears exposed to TPA. It can be observed that compound 1 is acting as a regulator of the immune response by causing a greater effect than PD and PDF7 on the concentration of IL-10, a cytokine with potent anti-inflammatory actions that is crucial in the prevention of inflammatory damage processes [35]. While TNF-α is released by dendritic cells and macrophages, its expression is controlled by the activation of TLR4 associated with the regulation of the transcriptional factor NF-κB [36]. It is therefore likely that the effects of 1, PD, and PDR7 are acting on this signaling pathway, so it is necessary to perform experiments that allow for the verification of this hypothesis. It was also observed that PDF7 has a similar behavior to the non-steroidal anti-inflammatory drug, indomethacin, which was used as a positive control. It is known that this drug inhibits the enzyme Cyclooxygenase 2 (COX-2), causing its anti-inflammatory effect; however, it is also capable of inhibiting COX-1 and inducing oxidative stress, which induces undesirable gastrointestinal effects [37]. The mechanism of action by which PDR7 is exerting the activity in question is unknown. It is expected that its therapeutic capacity will not have the same long-term consequences as indomethacin; for this, it is necessary to continue with a long-term and more refined study to define whether or not it has a toxicity profile.
In this study, microorganisms were selected primarily for their impact on the health sector as they generate resistance to commercial drugs. Several groups of microorganisms are resistant to antibiotics and antimicrobial agents, making the treatment of infectious diseases difficult. Hence, there is an extensive research effort to identify alternative ways to treat infections caused by microorganisms, including plant-based molecules [38]. In the present study, the PM extract inhibited the growth of all strains with good efficacy (MIC 6.25 and 12.5 μg/mL). The PM extract showed stronger antimicrobial activity than the PH and PD extracts. The antibacterial activity of the PM extract is comparable to the results reported by Nava-Solis et al. [19]; their methanolic extract of P. laevigata showed strong antimicrobial activity, especially against S. aureus (MIC = 0.62 mg/mL) and E. coli (MIC = 0.62 mg/mL). Sanchez [39], Khan et al. [40], and Raghavendra et al. [41] presented MICs of <100 µg/mL for different extracts from other Prosopis species. Among the 14 tested strains, the Gram-positive bacteria were more sensitive to the extracts. The efficacy of the extracts against Gram-positive bacteria may be attributed to their lack of an outer membrane, rendering them more susceptible to damage caused by active compounds, mainly polyphenols. The anti-fungal activity against Ca is also comparable with results obtained by Nava-Solis et al. [19]. The metabolic content of P. laevigata includes phytol, which can increase the accumulation of reactive oxygen species, causing an intracellular imbalance of the antioxidant system of P. aeruginosa and thus inhibiting this bacterium [42].
As demonstrated in the bioassays, the extract, fractions, and compounds isolated from P. laevigata showed significant effects associated with the inhibition of proinflammatory cytokines and against the growth of 13 pathogenic strains, suggesting potential therapeutic applications for infectious and inflammatory diseases.
This study opens the door to future lines of research and application, particularly in the development of new therapeutic agents. Furthermore, this study provides compelling evidence that P. laevigata can be classified as a phytopharmaceutical with pharmacological effects, highlighting its potential to combat microbial diseases and inflammatory processes. Future research should also focus on standardising the extraction process and analysing potential variations in chemical composition due to environmental factors. It is extremely important to validate the therapeutic efficacy and safety of the extract, fractions, EV, and other bioactive compounds to provide a more precise understanding of their toxicity, pharmacokinetics, synergistic effects, and bioavailability. Finally, to determine the clinical relevance of EV as a future candidate for the development of new phytopharmaceuticals, it is crucial to implement human clinical trials.

4. Materials and Methods

4.1. Plant Material

The aerial parts of P. laevigata were collected from the Ricardo Soto 1, las Calaveras, Higuerón (18°35′16″ N, 99°10′35″ W, 895 m above sea level) in Morelos State, Mexico, in December 2019. The sample specimen of this material was identified by M.C. Gabriel Flores at the Autonomous University of Morelos State (voucher code number: 39811); it was stored in the UAEM Herbarium. The fresh plant material of P. laevigata was dried at 30 °C.

4.2. Preparation of Extracts

Dried material (1.47 kg) was milled in a grinder (particle size 4 mm, Pulvex). The extraction process involved serial maceration with solvents of ascending polarity (n-hexane, dichloromethane and methanol) for 24 h. Three extracts (PH, PD, and PM) were evaluated in the anti-inflammatory and antibacterial assays described below. The macerations resulted in the following yields for each extract: 0.33% for PH, 1.49% for PD, and 8.79% for PM.

4.3. HPLC–Photo Diode Array (PDA) Analysis of the PM Extract

HPLC-PDA analysis used a Supelcosil LC-F column (4.6 mm × 250 mm internal diameter, 5 µm particle size; Sigma-Aldrich, Bellefonte, PA, USA). The mobile phase consisted of 0.5% trifluoroacetic acid aqueous solution (solvent A) and acetonitrile (solvent B). The gradient system was as follows: 0–1 min, 0% B; 2–3 min, 5% B; 4–20 min, 30% B; 21–23 min, 50% B; 24–25 min, 80% B; 26–27 min, 100% B; 28–30 min, 0% B. The flow rate was maintained at 0.9 mL/min, with a sample injection volume of 10 µL and a wavelength range detection of 190–600 nm. Terpenes were analysed at 220 nm and phenolic compounds at 350 nm.

4.4. Identification by GS-MS

The chemical composition of the PH and PD extracts was analysed on an Agilent gas chromatograph equipped with a quadruple mass detector in electron impact mode at 70 eV. Volatile compounds were separated on a HP 5MS (25 m long, 0.2 mm internal diameter, and 0.3 µm film thickness). The oven temperature was set at 40 °C for 1 min, followed by an increase from 40 to 250 °C at 10 °C/min, with maintenance at 250 °C for 20 min. The mass detector conditions were as follows: an interphase temperature of 200 °C and a mass acquisition range of 20–550 m/z. The injector and detector temperatures were set at 250 and 280 °C, respectively. Spitless injection mode was carried out with 1 µL of each fraction (3 mg/mL solution). The carrier gas was helium at a flow rate of 1 mL/min. The mass spectra were obtained in the time span of 30–35 min. The comparative percentages of each metabolite were estimated by equating their average peak area to the total areas, while the parameters necessary to determine compound classification, such as the molecular weight, formula, and structure of the active metabolites of the test sample, alongside its name, were corroborated. The compounds were identified by comparing the obtained mass spectra with the mass spectra from the literature. This endeavour allowed for the identification of 11 compounds.

4.5. Chromatographic Fractionation of the PD Extract

The PD extract (21.1 g) was adsorbed in silica gel and applied to a silica gel gravity column (51 g, 70–230 mesh, Merck, Darmstadt, Germany). A gradient of n-hexane/ethyl acetate was used to elute the column with an increase in polarity of 10% per 500 mL. This chromatographic process resulted in 35 fractions, which were grouped into 8 fractions according to the similarity of the constituents (PDR1–PDR8). The anti-inflammatory activity of the PDR3, PDR6, and PDR7 factions were evaluated.

4.6. Chromatographic Separation of the PDR7 Fraction to Obtain VE (1)

The PDR7 fraction (1.3 g) obtained from the PD extract was purified by successive open column reversed-phase chromatography using RP-18 silica gel (10 g, Sigma-Aldrich, St. Louis, MO, USA) as the stationary phase and a gradient of water/acetonitrile as the mobile phase, yielding 54 fractions with volumes of 10 mL. Thin-layer chromatography showed that subfractions 21 to 27 showed a single spot in the UV spectra (one compound), so they were pooled and analysed by one- and two-dimensional NMR. The compound was identified as VE (see Figure 3). This compound was evaluated as anti-inflammatory and antimicrobial.

4.7. Chromatographic Fractionation of the PM Extract

The PM extract (38.8 g) was adsorbed in silica gel and applied to a silica gel gravity column (100 g, 70–230 mesh, Merck, Darmstadt, Germany). A gradient of n-hexane/ethyl acetate was used to elute the column with an increase in polarity of 10% per 250 mL. This chromatographic process resulted in 36 fractions, which were grouped into 10 fractions according to the similarity of the constituents (PMR1–PMR10). Based on the chemical content, the antimicrobial activity of the PMR2, PMR5, PMR6, PMR7, and PMR10 fractions was evaluated.

4.8. Determination of the Anti-Inflammatory Activity

4.8.1. Experimental Animals

The methodology followed a published protocol [43]. Mice were acquired from Envigo México RMS (Mexico City, Mexico). The mice were used in accordance with NOM-062-ZOO-1999. This protocol was registered with the Ethics and Research Committee (R-2021-1702-010).

4.8.2. Mouse TPA-Induced Ear Oedema Model

Ear oedema was induced following a previously described method [43,44]. The extracts, fractions, and compound 1 were evaluated at a dose of 1 mg/ear. All treatments were dissolved in acetone. Each treatment was applied to the left ear immediately after the administration of TPA; the right was used as a control. The reduction in oedema (in milligrams) and the percentage of inhibition (%) were determined.

4.8.3. Quantification of the Pro-Inflammatory the Cytokines IL-10 and TNF-α

The mouse ears were dissected five hours after applying the treatments and TPA and frozen, further disintegrated into phosphate buffer (pH 7.0) with protease inhibitor (PMFS), and centrifuged for 5 min at 14,000 rpm. The supernatant was collected and stored at @70 °C for the ELISA analysis. In these samples, the cytokines IL-10 and TNF-α were quantified. The measurement technique was performed using a kit OptEIATM ELISA sets; BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer’s instructions. Briefly, we added 100 μL/well of the antibody uptake to 96-well plates; and the plates were incubated for 12 h at 4 °C. Then, the dish was washed with PBS (phosphate- buffered saline) solution (0.05% of Tween-20, 300 μL/well × three times). A total of 100 μL of PBS with fetal bovine serum (FBS) was added at 10%, pH 7.0, for 1 h at room temperature. The contents were discarded, and the plate was washed with PBS buffer (0.05% of Tween-20, 300 μL/well × three times). To the corresponding wells we added 100 μL of the standard, the target (PBS with PBS), and the test samples. The plate was incubated for 2 h at room temperature. The contents were discarded, and the plate was washed with PBS buffer (0.05% of Tween-20, 300 μL/well × five times). A total of 100 μL/well of a detection antibody and a streptavidin–horseradish peroxidase (HRP) enzyme solution was added. These plates were incubated for 1 h and washed with 300 μL/well × seven times with a PBS solution (combined with 0.05% of Tween-20).

4.9. Antimicrobial Activity

4.9.1. Microorganisms

Antibacterial activity was determined by the microdilution method using 7 Gram-positive strains (Staphylococcus aureus ATCC 29213, methicillin-resistant Staphylococcus aureus ATCC 43300, Staphylococcus epidermidis ATCC 35984, Staphylococcus epidermidis ATCC 12228, Staphylococcus epidermidis ATCC 49134, methicillin-resistant Staphylococcus haemolyticus derived from ATCC 29,970, and Enterococcus faecalis ATCC 29212), 6 Gram-negative strains (Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 8739, Escherichia coli ATCC 25922, Salmonella dublin ATCC 9676, and Enterobacter cloacae ATCC 700323), and one yeast (Candida albicans ATCC 10231). The microorganisms were provided by the Universidad Autónoma de Guerrero (UAGro). Two microliters of each strain were inoculated and incubated under constant temperature (20 ± 2 °C) and humidity (50 ± 5%) conditions.
The strains were maintained on Trypticase soy agar (Merck) at 37 °C for 24 h.

4.9.2. MIC

The MIC was determined based on a published method [45], with some changes in concentrations. All bacteria were standardised to 0.5 McFarland units (1.5 × 108 colony-forming units [CFU]/mL). Extracts and fractions were diluted with 200 μL of DMSO and 800 μL of H2O. Concentrations of 25, 50, 100, and 200 μg/mL were tested. Two microlitres of each strain were inoculated and incubated under controlled temperature (37 ± 2 °C) and humidity (13 ± 2%) conditions at 37 °C for 24 h. Gentamicin was used as a positive control (10 μg/mL), and DMSO (2%) was used as a negative control. All experiments were performed in triplicate.

4.10. Statistical Analysis

The data are expressed as the mean ± standard error of the mean (SEM). Statistical significance was determined using analysis of variance (ANOVA) followed by Dunnett’s and Bonferroni tests to compare each treatment with the vehicle and indomethacin groups. A p-value ≤ 0.05 was considered to indicate a statistically significant difference.

5. Conclusions

The PD extract of Prosopis laevigata showed the strongest anti-inflammatory effect, and the PM extract exerted the most pronounced antimicrobial effect. In the PD extract, compound 1 (VE) was isolated and identified and could be one of the compounds responsible for the anti-inflammatory effect according to the mouse TPA-induced ear oedema model and the observed concentration of pro-inflammatory cytokines IL-10 and TNF-α. On the other hand, flavonoid-type compounds present in the PM extract and its fractions may be responsible for the antibacterial activity.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/plants14071118/s1, Figures S1 and S2: TLC, UV, and HPLC data. Figures S3–S6: 1H NMR, 13C NMR, DEPT, HSQC, and HMBC.

Author Contributions

M.G.-C., M.H.-R., M.D.P.-G., D.O.S.-S. and E.J.-F. conceived and designed the experiments; M.G.-C., M.H.-R., M.D.P.-G., E.A.B.-G. and A.Z. analysed the chemical and biological data; P.H.-H. and B.E.U.-H. performed the chemical and biological experiments; M.G.-C. and A.S.G.-R. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by FUNDACION IMSS A.C.

Data Availability Statement

Data is contained within the article or Supplementary Materials.

Acknowledgments

This research was supported by a grant from CIS-IMSS (R-2021-1702-01).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Muteeb, G.; Rehman, M.T.; Shahwan, M.; Aatif, M. Origin of antibiotics and antibiotic resistance, and their impacts on drugs development: A narrative review. Pharmaceuticals 2023, 16, 1615. [Google Scholar] [CrossRef]
  2. Ahmed, S.K.; Hussein, S.; Qurbani, K.; Ibrahim, R.H.; Fareeq, A.; Mahmood, K.A.; Mohamed, M.G. Antimicrobial resistance: Impacts, challenges, and future prospects. J. Med. Surg. Public. Health 2024, 2, 100081. [Google Scholar]
  3. Pham, M.N.; Nishimura, F.; Wei-Lan, J.C.; Shiong-Khoo, K. Recent advancement of eliminating antibiotic bacteria and antibiotic resistance genes in livestock waste: A review. Environ. Technol. Innov. 2024, 36, 103751. [Google Scholar]
  4. Reygaert, W.C. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018, 4, 482–501. [Google Scholar] [PubMed]
  5. Macias, J.; Kahly, O.; Pattik-Edward, R.; Khan, S.; Qureshi, A.; Shaik, A.; Shala, A.; Shah, D. Sepsis: A systematic review of antibiotic resistance and antimicrobial therapies. Mod. Res. Inflamm. 2022, 11, 9–23. [Google Scholar]
  6. O’Neill, J. Tackling drug-resistant infections globally: Final report and recommendations. In Review on Antimicrobial Resistance; Wellcome Trust & HM Government: London, UK, 2016; pp. 10–16. [Google Scholar]
  7. Rojas-Jiménez, S.; Valladares-Cisneros, M.G.; Salinas-Sánchez, D.O.; Pérez-Ramos, J.; Sánchez-Pérez, L.; Pérez-Gutiérrez, S.; Campos-Xolalpa, N. Anti-inflammatory and cytotoxic compounds isolated from plants of Euphorbia genus. Molecules 2024, 29, 1083. [Google Scholar] [CrossRef]
  8. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017, 9, 7204–7218. [Google Scholar]
  9. Matotoka, M.M.; Mashabela, G.T.; Masoko, P. Phytochemical content, antibacterial activity, and antioxidant, anti-Inflammatory, and cytotoxic effects of traditional medicinal plants against respiratory tract bacterial pathogens. Evid. Based Complement. Alternat Med. 2023, 2023, 1243438. [Google Scholar]
  10. Liu, Q.; Meng, X.; Li, Y.; Zhao, C.N.; Tang, G.Y.; Li, H.B. Antibacterial and antifungal activities of spices. Int. J. Mol. Sci. 2017, 18, 1283. [Google Scholar] [CrossRef] [PubMed]
  11. El-Saber-Batiha, G.; Magdy-Beshbishy, A.; Wasef, L.G.; Elewa, Y.H.A.; Al-Sagan, A.A.; Abd-El-Hack, M.E.; Taha, A.E.; Abd-Elhakim, Y.M.; Prasad-Devkota, H. Chemical constituents and pharmacological activities of garlic (Allium sativum L.): A review. Nutrients 2020, 12, 872. [Google Scholar] [CrossRef]
  12. Zhao, T.; Li, C.; Wang, S.; Song, X. Green tea (Camellia sinensis): A review of its phytochemistry, pharmacology, and toxicology. Molecules 2022, 27, 3909. [Google Scholar] [CrossRef] [PubMed]
  13. Cheng, C.; Sha, Z.; Chen, X.; Zhang, W.; Shi, L.Y. Rosmarinic acid bolsters antibacterial immunity activity of macrophages by up-regulating PINK1/Parkin-mediated mitophagy. Zhongguo Zhong Yao Za Zhi 2022, 47, 6450–6456. [Google Scholar] [PubMed]
  14. Ayustaningwarno, F.; Anjani, G.; Ayu, A.M.; Fogliano, V. A critical review of Ginger’s (Zingiber officinale) antioxidant, anti-inflammatory, and immunomodulatory activities. Front. Nutr. 2024, 11, 1364836. [Google Scholar]
  15. Henciya, S.; Seturaman, P.; James, R.A.; Tsai, Y.; Nikam, R.; Wu, Y.; Dahms, H.; Chang, F.R. Biopharmaceutical potentials of Prosopis spp. (Mimosaceae, Leguminosa). J. Food Drug Anal. 2017, 25, 187–196. [Google Scholar]
  16. Hernández-Ruiz, J.; Aguilar-Marcelino, L.; Marín, J.A.H.; Avalos, A.M.C.; Huerta, I.A.; Arriaga, A.I.M. Use of Prosopis on feed nutrition: Challenges and opportunities. In Complementary and Alternative Medicine: Feed Additives; Abbas, R.Z., Akhtar, T., Asrar, R., Khan, A.M.A., Saeed, Z., Eds.; Unique Scientific Publishers: Faisalabad, Pakistan, 2024; pp. 163–170. [Google Scholar]
  17. Pasiecznik, N.M. Prosopis: Pest or providence, weed or wonder tree? Eur. Trop. For. Res. Netw. Newslett 1999, 28, 12e4. [Google Scholar]
  18. Argueta Villamar, A.; Cano Asseleih, L.M.; Rodarte, M.L. Atlas de las Plantas de la Medicina Tradicional Mexicana, 1st ed.; Instituto Nacional Indigenista: Mexico City, Mexico, 1994. [Google Scholar]
  19. Nava-Solis, U.; Rodriguez-Canales, M.; Hernandez-Hernandez, A.B.; Velasco-Melgoza, D.A.; Moreno-Guzman, B.P.; Rodriguez-Monroy, M.A.; Canales-Martinez, M.M. Antimicrobial activity of the methanolic leaf extract of Prosopis laevigata. Sci. Rep. 2022, 12, 20807. [Google Scholar]
  20. Salinas-Sánchez, D.O.; Arteaga-Najera, G.L.; León-Rivera, I.; Dorado-Ramírez, O.; Valladares-Cisneros, M.G.; Navarro-García, V.M. Antimicrobial activity of medicinal plants from the Huautla Sierra Biosphere Reserve in Morelos (Mexico). Polibotánica 2009, 28, 1405–2768. [Google Scholar]
  21. Delgado-Núñez, E.J.; Zamilpa, A.; González-Cortazar, M.; Olmedo-Juárez, A.; Cardoso-Taketa, A.; Sánchez-Mendoza, E.; Tapia-Maruri, D.; Salinas-Sánchez, D.O.; Mendoza-de Gives, P. Isorhamnetin: A nematocidal flavonoid from Prosopis laevigata leaves against Haemonchus contortus eggs and larvae. Biomolecules 2020, 10, 773. [Google Scholar] [CrossRef]
  22. Ramirez-Arteaga, M.; Valladares, M.G.; González-Rodríguez, J.G. Use of Prosopis laevigata as a corrosion inhibitor for al in H2SO4. Int. J. Electrochem. Sci. 2013, 8, 6864–6877. [Google Scholar]
  23. Matta, D.; Nanda, H.; Mahalingam, G. Phytopharmaceutical potentials of Prosopis laevigata, Symplocos cochinchinensis and Nymphacea alba: A review. Asian J. Pharm. Clin. Res. 2017, 10, 63–68. [Google Scholar]
  24. Palacios, R.A. Los mezquites mexicanos: Biodiversidad y distribución geográfica; Sociedad Argentina de Botánica. Bol. Soc. Argent. Bótanica 2006, 41, 99–121. [Google Scholar]
  25. Galindo-Almanza, S.; García-Moya, E. Usos del mezquite (Prosopis L.) en el Altiplano Potosino. Agrociencia 1986, 63, 7–16. [Google Scholar]
  26. Hernández, T.; Canales, M.; Avila, J.G.; Duran, A.; Caballero, J.; De Vivar, A.R.; Lira, R. Ethnobotany and antibacterial activity of some plants used in traditional medicine of Zapotitlán de las Salinas, Puebla (México). J. Ethnopharmacol. 2003, 88, 181–188. [Google Scholar] [PubMed]
  27. García-Andrade, M.; González-Laredo, R.F.; Rocha-Guzmán, N.E.; Gallegos-Infante, J.A.; Rosales-Castro, M.; Medina-Torres, L. Mesquite leaves (Prosopis laevigata), a natural resource with antioxidant capacity and cardioprotection potential. Ind. Crops Prod. 2017, 44, 336–342. [Google Scholar]
  28. You, B.R.; Yoo, J.M.; Baek, S.Y.; Kim, M.R. Anti-inflammatory effect of aged black garlic on 12-O-tetradecanoylphorbol-13-acetate-induced dermatitis in mice. Nutr. Res. Pract. 2019, 13, 189–195. [Google Scholar]
  29. Nakamura, A.; Uratsuji, H.; Yamada, Y.; Hashimoto, K.; Nozawa, N.; Matsumoto, T. Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate-and 2, 4, 6-trinitrophenyl chloride–induced skin inflammation in mice. Mycoses 2020, 63, 189–196. [Google Scholar]
  30. Murakawa, M.; Yamaoka, K.; Tanaka, Y.; Fukuda, Y. Involvement of tumor necrosis factor (TNF)-α in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice. Biochem. Pharmacol. 2006, 71, 1331–1336. [Google Scholar]
  31. Darwish, S.R.; Fares, M.; Hammada, H.; Yassin, A.; Ghareeb, D.; Harraz, F.; Shawky, E. Comparative metabolomics applied for valorization of Mesquite (Prosopis juliflora Sw. DC.) by-products as potential source of anti-inflammatory functional constituents. Ind. Crops Prod. 2022, 176, 114344. [Google Scholar]
  32. Silva, R.O.; Sousa, F.B.M.; Damasceno, S.R.B.; Carvalho, N.S.; Silva, V.G.; Oliveira, F.R.M.A.; Sousa, D.P.; Aragão, K.S.; Barbosa, A.L.; Freitas, R.M.; et al. Phytol, a diterpene alcohol, inhibits the inflammatory response by reducing cytokine production and oxidative stress. Fundam. Clin. Pharmacol. 2014, 28, 455–464. [Google Scholar]
  33. Pankaj, H.N.; Narendra, D.P.; Dhananjay, V.M. Ethanopharmacological anti-inflammatory study of phytol in ethanol extract of Woodfordia floribunda Salisb. Ann. Phytomedicine 2022, 11, 426–437. [Google Scholar]
  34. Carvalho, A.M.S.; Heimfarth, L.; Pereira, E.W.M.; Oliveira, F.S.; Menezes, I.R.A.; Coutinho, H.D.M.; Quintans-Júnior, L.J. Phytol, a chlorophyll component, produces antihyperalgesic, anti-inflammatory, and antiarthritic effects: Possible NFκB pathway involvement and reduced levels of the proinflammatory cytokines TNF-α and IL-6. J. Nat. Prod. 2020, 83, 1107–1117. [Google Scholar] [PubMed]
  35. Sabat, R.; Grütz, G.; Warszawska, K.; Kirsch, S.; Witte, E.; Wolk, K.; Geginet, J. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010, 21, 331–344. [Google Scholar] [CrossRef]
  36. Wei, W.C.; Lin, S.Y.; Chen, Y.J.; Wen, C.C.; Huang, C.Y.; Palanisamy, A.; Yang, N.S.; Sheu, J.H. Topical application of marine briarane-type diterpenes effectively inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and dermatitis in murine skin. J. Biomed. Sci. 2011, 18, 94. [Google Scholar]
  37. Ekinci, B.; Süleyman, B.; Mammadov, R.; Bulut, S.; Özçiçek, A.; Ergul, C.; Süleyman, H. Beneficial interaction of pycnogenol with indomethacin in rats. Gen. Physiol. Biophys. 2022, 41, 473–481. [Google Scholar] [PubMed]
  38. Cattaneo, F.; Sayago, J.E.; Alberto, M.R.; Zampini, I.C.; Ordoñez, R.M.; Chamorro, V.; Isla, M.I. Anti-inflammatory and antioxidant activities, functional properties and mutagenicity studies of protein and protein hydrolysate obtained from Prosopis alba seed flour. Food Chem. 2014, 161, 391–399. [Google Scholar]
  39. Saánchez, E. Antibacterial and antibiofilm activity of methanolic plant extracts against nosocomial microorganisms. Evid. Based Complement. Altern. Med. 2016, 2016, 1572697. [Google Scholar]
  40. Khan, R.; Zakir, M.; Afaq, S.H.; Latif, A.; Khan, A.U. Activity of solvent extracts of Prosopis spicigera, Zingiber officinale and Trachyspermum ammi against multidrug resistant bacterial and fungal strains. J. Infect. Dev. Ctries. 2010, 4, 292–300. [Google Scholar]
  41. Raghavendra, M.; Satish, S.; Raveesha, K. Alkaloid extracts of Prosopis juliflora (Sw) DC. (Mimosaceae) against Alternaria alternata. Biopestic. Int. 2009, 2, 56–59. [Google Scholar]
  42. Lee, W.; Woo, E.R.; Lee, D.G. Phytol has antibacterial property by inducing oxidative stress response in Pseudomonas aeruginosa. Free Radic. Res. 2016, 50, 1309–1318. [Google Scholar]
  43. Salinas-Sánchez, D.O.; Herrera-Ruiz, M.; Pérez, S.; Jiménez-Ferrer, E.; Zamilpa, A. Anti-inflammatory activity of hautriwaic acid isolated from Dodonaea viscosa leaves. Molecules 2012, 17, 4292–4299. [Google Scholar] [CrossRef]
  44. Payá, M.; Ferrándiz, M.L.; Sanz, M.J.; Bustos, G.; Blasco, R.; Ríos, J.L.; Alcaráz, M.J. Study of the antioedema activity of some seaweed and sponge extracts from the Mediterranean coast in mice. Phytother. Res. 2010, 7, 159–162. [Google Scholar]
  45. Sarker, S.D.; Nahar, L.; Kumarasamy, Y. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. Methods 2007, 42, 321–324. [Google Scholar] [PubMed]
Plants 14 01118 g001
Figure 1. Chemical profiles: (A) Prosopis laevigata methanolic extract at 350 nm; (B) rutin (2); (C) quercetin 3-O-glucoside (3). UV spectrum: (D) Prosopis laevigata methanolic extract; (E) rutin; (F) quercetin 3-O-glucoside (3).
Figure 1. Chemical profiles: (A) Prosopis laevigata methanolic extract at 350 nm; (B) rutin (2); (C) quercetin 3-O-glucoside (3). UV spectrum: (D) Prosopis laevigata methanolic extract; (E) rutin; (F) quercetin 3-O-glucoside (3).
Plants 14 01118 g001
Plants 14 01118 g003aPlants 14 01118 g003b
Figure 3. Effects of different P. laevigata treatments—i.e., dichloromethane extract (PD), fractions from this extract (PDR7), and compound 1—on the concentration of IL-10 (A) and TNF-α (B) on the ears of mice stimulated with a phorbol ester (TPA). Graphical representation showing media ± SD (n = 5) with one-way ANOVA and post hoc Bonferroni (* p ≤ 0.05) when compared with the TPA group.
Figure 3. Effects of different P. laevigata treatments—i.e., dichloromethane extract (PD), fractions from this extract (PDR7), and compound 1—on the concentration of IL-10 (A) and TNF-α (B) on the ears of mice stimulated with a phorbol ester (TPA). Graphical representation showing media ± SD (n = 5) with one-way ANOVA and post hoc Bonferroni (* p ≤ 0.05) when compared with the TPA group.
Plants 14 01118 g003aPlants 14 01118 g003b
Table 1. The gas chromatography–mass spectrometry profile of the Prosopis laevigata n-hexane extract.
Table 1. The gas chromatography–mass spectrometry profile of the Prosopis laevigata n-hexane extract.
Peak
No		NameRetention Time
(min)		Relative
Area (%)		Mw
(g/mol)		Type of Compound
11,54-Dibromotetrapentacontane21.374.27917.2Alkane
2Hexanedioic acid22.225.64370.6Fatty acid
3Tetracontane23.133.47563.1Alkane
46,6′-di-tert-butyl-4,4′-diethyl-2,2′-methylenediphenol23.369.64368.55Alkylated phenol
5Heptacosane24.242.72380.7Alkane
6Tetratetracontane25.643.68619.2Alkane
7Squalene27.891.48410.73Triterpene
Table 2. The gas chromatography–mass spectrometry profile of the Prosopis laevigata dichloromethane extract.
Table 2. The gas chromatography–mass spectrometry profile of the Prosopis laevigata dichloromethane extract.
Peak
No.		NameRetention Time
(min)		Relative
Area (%)		Mw
(g/mol)		Type of Compound
16-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydrobenzofuran-2(4H)-one 13.7712.87196.24Benzofuran
2Phytol 19.7770.11296.53Diterpene alcohol
3Bis[(2S)-2-ethylhexyl] hexanedioate22.2217.0370.6Fatty acid
Table 3. Anti-inflammatory activity of the Prosopis laevigata extracts.
Table 3. Anti-inflammatory activity of the Prosopis laevigata extracts.
TreatmentOedema (mg)Oedema Inhibition (%)
VEH11.43 ± 0.87–
INDO4.00 ± 1.40 *65.01
PH4.48 ± 1.83 *60.81
PD2.74 ± 0.68*75.96
PM4.54 ± 1.41 *60.29
Abbreviations: INDO, indomethacin; PD, P. laevigata dichloromethane extract; PH, P. laevigata n-hexane extract; PM, P. laevigata methanolic extract; VEH, vehicle. * p ≤ 0.05, Anova post hoc Dunnet in comparison with vehicule. Highlighted in bold indicates greater effect.
Table 5. Anti-inflammatory activity of the fractions and compound (1) from the dichloromethane extract of Prosopis laevigata.
Table 5. Anti-inflammatory activity of the fractions and compound (1) from the dichloromethane extract of Prosopis laevigata.
TreatmentOedema (mg)Oedema Inhibition (%)
VEH12.78 ± 2.64–
INDO4.00 ± 1.40 *65.01
PDR35.55 ± 2.03 *56.58
PDR64.41 ± 2.55 *65.45
PDR76.23 ± 1.70 *51.23
VE (1)1.90 ± 0.63 *85.13
Abbreviations: 1, ethyl veratrate; INDO, indomethacin; PDR, fractions of the P. laevigata dichloromethane extract; VEH, vehicle. * p ≤ 0.05, Anova post hoc Dunnet in comparison with vehicule. Highlighted in bold indicates greater effect.
Table 6. Antimicrobial activity of the Prosopis laevigata extracts.
Table 6. Antimicrobial activity of the Prosopis laevigata extracts.
Bacterial Clinical IsolateMinimum Inhibitory Concentration (μg/mL)
PHPDPM
Staphylococcus aureus ATCC 292132002006.25
Methicillin-resistant Staphylococcus aureus ATCC 4330020012.56.25
Staphylococcus epidermidis ATCC 3598420012.56.25
Staphylococcus epidermidis ATCC 12228506.256.25
Staphylococcus epidermidis ATCC 49134-2006.25
Staphylococcus haemolyticus derived from ATCC 29970-2006.25
Enterococcus faecalis ATCC 292126.256.256.25
Klebsiella pneumoniae ATCC 7006036.2512.56.25
Pseudomonas aeruginosa ATCC 278536.2512.56.25
Escherichia coli ATCC 8739--12.5
Escherichia coli ATCC 259226.252512.5
Salmonella dublin ATCC 96766.256.256.25
Enterobacter cloacae ATCC 70032312.512.512.5
Candida albicans ATCC 102316.256.256.25
The values correspond to the average (n = 3). The following organisms were evaluated: seven Gram-positive strains, six Gram-negative strains, and one yeast. The positive control was gentamicin (10 µg/mL), and the negative control was 2% dimethyl sulfoxide. Abbreviations: PD, P. laevigata dichloromethane extract; PH, P. laevigata n-hexane extract; PM, P. laevigata methanolic extract.
Table 7. Antibacterial activity of fractions of the methanolic extract (PMR2, PMR5, PMR6, PMR7, PMR10), the dichloromethane extract (PDR7), and compound 1 of Prosopis laevigata.
Table 7. Antibacterial activity of fractions of the methanolic extract (PMR2, PMR5, PMR6, PMR7, PMR10), the dichloromethane extract (PDR7), and compound 1 of Prosopis laevigata.
Bacterial Clinical IsolateMinimum Inhibitory Concentration
(μg/mL)
Fractions
PMR2PMR5PMR6PMR7PMR10PDR71
Staphylococcus aureus ATCC 29213--6.25256.25--
Methicillin-resistant Staphylococcus aureus ATCC 43300--6.252512.5100-
Staphylococcus epidermidis ATCC 3598425-6.256.256.2525-
Staphylococcus epidermidis ATCC 12228200-6.252525--
Staphylococcus epidermidis ATCC 49134--6.2512.512.5--
Staphylococcus haemolyticus derived from ATCC 29970--6.2512.512.5--
Enterococcus faecalis ATCC 2921225256.256.2550100-
Klebsiella pneumoniae ATCC 70060325-6.256.256.25-2
Pseudomonas aeruginosa ATCC 2785325256.25256.251008
Escherichia coli ATCC 8739--2520050200-
Escherichia coli ATCC 25922252512.52525-8
Salmonella dublin ATCC 96766.256.256.256.256.25252
Enterobacter cloacae ATCC 70032312.512.512.512.512.2525-
Candida albicans ATCC 102316.256.256.256.256.25 2
The values correspond to the average (n = 3). The following organisms were evaluated: seven Gram-positive strains, six Gram-negative strains, and one yeast. The positive control was gentamicin (10 µg/mL), and the negative control was 2% dimethyl sulfoxide.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

González-Cortazar, M.; Salinas-Sánchez, D.O.; Herrera-Ruiz, M.; Hernández-Hernández, P.; Zamilpa, A.; Jiménez-Ferrer, E.; Utrera-Hernández, B.E.; Pérez-García, M.D.; Gutiérrez-Roman, A.S.; Ble-González, E.A. Chemical Profile Analysis of Prosopis laevigata Extracts and Their Topical Anti-Inflammatory and Antibacterial Activities. Plants 2025, 14, 1118. https://doi.org/10.3390/plants14071118

AMA Style

González-Cortazar M, Salinas-Sánchez DO, Herrera-Ruiz M, Hernández-Hernández P, Zamilpa A, Jiménez-Ferrer E, Utrera-Hernández BE, Pérez-García MD, Gutiérrez-Roman AS, Ble-González EA. Chemical Profile Analysis of Prosopis laevigata Extracts and Their Topical Anti-Inflammatory and Antibacterial Activities. Plants. 2025; 14(7):1118. https://doi.org/10.3390/plants14071118

Chicago/Turabian Style

González-Cortazar, Manasés, David Osvaldo Salinas-Sánchez, Maribel Herrera-Ruiz, Paulina Hernández-Hernández, Alejandro Zamilpa, Enrique Jiménez-Ferrer, Beatriz E. Utrera-Hernández, Ma. Dolores Pérez-García, Ana S. Gutiérrez-Roman, and Ever A. Ble-González. 2025. "Chemical Profile Analysis of Prosopis laevigata Extracts and Their Topical Anti-Inflammatory and Antibacterial Activities" Plants 14, no. 7: 1118. https://doi.org/10.3390/plants14071118

APA Style

González-Cortazar, M., Salinas-Sánchez, D. O., Herrera-Ruiz, M., Hernández-Hernández, P., Zamilpa, A., Jiménez-Ferrer, E., Utrera-Hernández, B. E., Pérez-García, M. D., Gutiérrez-Roman, A. S., & Ble-González, E. A. (2025). Chemical Profile Analysis of Prosopis laevigata Extracts and Their Topical Anti-Inflammatory and Antibacterial Activities. Plants, 14(7), 1118. https://doi.org/10.3390/plants14071118

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop